BCRX BioCryst Pharmaceuticals, Inc.

+0  (4%)
Previous Close 8.85
Open 8.82
Price To book 421.43
Market Cap 680.39M
Shares 73,955,000
Volume 1,566,405
Short Ratio 5.21
Av. Daily Volume 1,804,900

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Phase 2 interim data released February 27, 2017.
BCX7353 - APeX-1
Reduce or eliminate attacks in HAE patients
Approved Dec 22 2014
Peramivir - Study 303

Latest News

  1. Wait for the Pullback on BioCryst Pharmaceuticals
  2. Don't Let Offerings Blindside Your Thesis
  3. BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
  4. BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue?
  5. BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  6. It’s time to vaccinate your investments against a deadly bird flu
  7. BioCryst Pharmaceuticals Prices Public Offering of Common Stock
  8. Biotech Premarket Movers: Spectrum, BioCryst, Curis
  9. The Reason Behind BioCryst Pharmaceuticals, Inc.'s 12% Pop Higher
  10. BioCryst Pharmaceuticals Commences Public Offering of Common Stock
  11. Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session
  12. BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  14. Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Sarepta Therapeutics and BioCryst Pharmaceuticals
  15. BioCryst Pharmaceuticals, Inc. (BCRX): A Discount Entry?
  16. Here's Why BioCryst Pharmaceuticals Inc. Catapulted Higher by as Much as 17%
  17. BioCryst 4Q Net 6 Cents a Share Beats Street
  18. Edited Transcript of BCRX earnings conference call or presentation 27-Feb-17 2:00pm GMT
  19. BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns
  20. Biotech Premarket Movers: BioCryst, Sangamo, Cempra
  21. BioCryst Pharmaceuticals Stock Drops After Reporting 4Q Loss
  22. BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
  23. BioCryst reports 4Q loss
  24. BioCryst Reports Third Quarter 2016 Financial Results
  25. BioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) Nonclinical Results in Zika Virus Infection at IDWeek 2016
  26. BioCryst to Announce Third Quarter 2016 Financial Results November 7
  27. BioCryst Closes $23 Million Senior Credit Facility
  28. BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model
  29. BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema
  30. BioCryst Reports Second Quarter 2016 Financial Results
  31. BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases
  32. BioCryst to Present at Two Upcoming Investor Conferences
  33. BioCryst Reports First Quarter 2016 Financial Results
  34. BioCryst to Announce First Quarter 2016 Financial Results May 5
  35. BioCryst to Present at Two Upcoming Investor Conferences